BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients 2017;9:E387. [PMID: 28420094 DOI: 10.3390/nu9040387] [Cited by in Crossref: 166] [Cited by in F6Publishing: 117] [Article Influence: 41.5] [Reference Citation Analysis]
Number Citing Articles
1 Jimenez V, Jambrina C, Casana E, Sacristan V, Muñoz S, Darriba S, Rodó J, Mallol C, Garcia M, León X, Marcó S, Ribera A, Elias I, Casellas A, Grass I, Elias G, Ferré T, Motas S, Franckhauser S, Mulero F, Navarro M, Haurigot V, Ruberte J, Bosch F. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med 2018;10:e8791. [PMID: 29987000 DOI: 10.15252/emmm.201708791] [Cited by in Crossref: 75] [Cited by in F6Publishing: 55] [Article Influence: 37.5] [Reference Citation Analysis]
2 Tang L, Wu Y, Tian M, Sjöström CD, Johansson U, Peng XR, Smith DM, Huang Y. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab 2017;313:E563-76. [PMID: 28811292 DOI: 10.1152/ajpendo.00086.2017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
3 Semmler G, Wernly S, Bachmayer S, Wernly B, Schwenoha L, Huber-Schönauer U, Stickel F, Niederseer D, Aigner E, Datz C. Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk-A Single-Center Cross-Sectional Study. Clin Transl Gastroenterol 2021;12:e00326. [PMID: 33821832 DOI: 10.14309/ctg.0000000000000326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Gerber LH, Weinstein AA, Mehta R, Younossi ZM. Importance of fatigue and its measurement in chronic liver disease. World J Gastroenterol 2019;25:3669-83. [PMID: 31391765 DOI: 10.3748/wjg.v25.i28.3669] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Ðanić M, Stanimirov B, Pavlović N, Goločorbin-Kon S, Al-Salami H, Stankov K, Mikov M. Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. Front Pharmacol 2018;9:1382. [PMID: 30559664 DOI: 10.3389/fphar.2018.01382] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 11.7] [Reference Citation Analysis]
6 Deenin W, Malakul W, Boonsong T, Phoungpetchara I, Tunsophon S. Papaya improves non-alcoholic fatty liver disease in obese rats by attenuating oxidative stress, inflammation and lipogenic gene expression. World J Hepatol 2021;13:315-27. [PMID: 33815675 DOI: 10.4254/wjh.v13.i3.315] [Reference Citation Analysis]
7 Bravo M, Raurell I, Hide D, Fernández-Iglesias A, Gil M, Barberá A, Salcedo MT, Augustin S, Genescà J, Martell M. Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH. Sci Rep 2019;9:20183. [PMID: 31882668 DOI: 10.1038/s41598-019-56366-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
8 Armutcu F. Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions. Inflamm Res 2019;68:825-39. [PMID: 31327029 DOI: 10.1007/s00011-019-01271-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
9 Wasilewska N, Lebensztejn DM. Non-alcoholic fatty liver disease and lipotoxicity. Clin Exp Hepatol 2021;7:1-6. [PMID: 34027109 DOI: 10.5114/ceh.2021.104441] [Reference Citation Analysis]
10 Ni Y, Ni L, Zhuge F, Fu Z. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2020;64:e2000375. [PMID: 32738185 DOI: 10.1002/mnfr.202000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
11 Liou CJ, Dai YW, Wang CL, Fang LW, Huang WC. Maslinic acid protects against obesity-induced nonalcoholic fatty liver disease in mice through regulation of the Sirt1/AMPK signaling pathway. FASEB J. 2019;33:11791-11803. [PMID: 31361524 DOI: 10.1096/fj.201900413rrr] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
12 Suwarto S, Diahtantri RA, Hidayat MJ, Widjaya B. Nonalcoholic fatty liver disease is associated with increased hemoconcentration, thrombocytopenia, and longer hospital stay in dengue-infected patients with plasma leakage. PLoS One. 2018;13:e0205965. [PMID: 30332476 DOI: 10.1371/journal.pone.0205965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Alizai PH, Lurje I, Kroh A, Schmitz S, Luedde T, Andruszkow J, Neumann UP, Ulmer F. Noninvasive Evaluation of Liver Function in Morbidly Obese Patients. Gastroenterol Res Pract 2019;2019:4307462. [PMID: 30863439 DOI: 10.1155/2019/4307462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Jiang M, Wu N, Chen X, Wang W, Chu Y, Liu H, Li W, Chen D, Li X, Xu B. Pathogenesis of and major animal models used for nonalcoholic fatty liver disease. J Int Med Res 2019;47:1453-66. [PMID: 30871397 DOI: 10.1177/0300060519833527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
15 Li X, Xia M, Ma H, Hu Y, Yan H, He W, Lin H, Zhao NQ, Gao J, Gao X. Liver fat content is independently associated with microalbuminuria in a normotensive, euglycaemic Chinese population: a community-based, cross-sectional study. BMJ Open 2021;11:e044237. [PMID: 34187816 DOI: 10.1136/bmjopen-2020-044237] [Reference Citation Analysis]
16 Dang Y, Xu J, Yang Y, Li C, Zhang Q, Zhou W, Zhang L, Ji G. Ling-gui-zhu-gan decoction alleviates hepatic steatosis through SOCS2 modification by N6-methyladenosine. Biomedicine & Pharmacotherapy 2020;127:109976. [DOI: 10.1016/j.biopha.2020.109976] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Stošić-Grujičić S, Saksida T, Miljković Đ, Stojanović I. MIF and insulin: Lifetime companions from common genesis to common pathogenesis. Cytokine 2020;125:154792. [PMID: 31400637 DOI: 10.1016/j.cyto.2019.154792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Zhao D, Zhang S, Wang X, Gao D, Liu J, Cao K, Chen L, Liu R, Liu J, Long J. ATG7 regulates hepatic Akt phosphorylation through the c-JUN/PTEN pathway in high fat diet-induced metabolic disorder. FASEB J 2019;33:14296-306. [PMID: 31645130 DOI: 10.1096/fj.201901414RR] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ota T. Immune regulation of glucose and lipid metabolism. Diabetol Int 2017;8:257-67. [PMID: 30603331 DOI: 10.1007/s13340-017-0331-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 López-Trujillo MA, Olivares-Gazca JM, Cantero-Fortiz Y, García-Navarrete YI, Cruz-Mora A, Olivares-Gazca JC, Murrieta-Álvarez I, León-Peña AA, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance. Clin Appl Thromb Hemost 2019;25:1076029619888694. [PMID: 31840531 DOI: 10.1177/1076029619888694] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cui H, Zhang X. Occurrence and clinical management of nonalcoholic fatty liver disease in obesity patients: a literature review. Journal of Pediatric Endocrinology and Metabolism 2020;33:579-84. [DOI: 10.1515/jpem-2019-0595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Luo P, Qin C, Zhu L, Fang C, Zhang Y, Zhang H, Pei F, Tian S, Zhu XY, Gong J, Mao Q, Xiao C, Su Y, Zheng H, Xu T, Lu J, Zhang J. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6. Hepatology 2018;68:1786-803. [PMID: 29698567 DOI: 10.1002/hep.30062] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
23 Liou CJ, Wu SJ, Shen SC, Chen LC, Chen YL, Huang WC. Phloretin ameliorates hepatic steatosis through regulation of lipogenesis and Sirt1/AMPK signaling in obese mice. Cell Biosci 2020;10:114. [PMID: 33014333 DOI: 10.1186/s13578-020-00477-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 McAlister E, Kirkby M, Domínguez-Robles J, Paredes AJ, Anjani QK, Moffatt K, Vora LK, Hutton ARJ, McKenna PE, Larrañeta E, Donnelly RF. The role of microneedle arrays in drug delivery and patient monitoring to prevent diabetes induced fibrosis. Adv Drug Deliv Rev 2021;175:113825. [PMID: 34111467 DOI: 10.1016/j.addr.2021.06.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Di Bonito P, Pacifico L, Licenziati MR, Maffeis C, Morandi A, Manco M, del Giudice EM, Di Sessa A, Campana G, Moio N, Baroni MG, Chiesa C, De Simone G, Valerio G, Forziato C, Gilardini L, Loche S, Tornese G. Elevated blood pressure, cardiometabolic risk and target organ damage in youth with overweight and obesity. Nutrition, Metabolism and Cardiovascular Diseases 2020;30:1840-7. [DOI: 10.1016/j.numecd.2020.05.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
26 Xiao Z, Chu Y, Qin W. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease. Life Sci 2020;256:117997. [PMID: 32585242 DOI: 10.1016/j.lfs.2020.117997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
27 Storck LJ, Imoberdorf R, Ballmer PE. Nutrition in Gastrointestinal Disease: Liver, Pancreatic, and Inflammatory Bowel Disease. J Clin Med 2019;8:E1098. [PMID: 31349549 DOI: 10.3390/jcm8081098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
28 Tsukamoto K, Takemoto M, Kubota Y, Taniguchi T, Motegi SI, Taniguchi A, Nakagami H, Maezawa Y, Koshizaka M, Kato H, Mori S, Kuzuya M, Yokote K. Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome. Geriatr Gerontol Int 2021;21:133-8. [PMID: 33258561 DOI: 10.1111/ggi.14095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sun X, Ji Y, Tahir A, Kang J. Network Pharmacology Combined with Transcriptional Analysis to Unveil the Biological Basis of Astaxanthin in Reducing the Oxidative Stress Induced by Diabetes Mellitus. Diabetes Metab Syndr Obes 2020;13:4281-95. [PMID: 33204134 DOI: 10.2147/DMSO.S274315] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Luo Y, Lin H. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immun Inflamm Dis 2021;9:59-73. [PMID: 33332766 DOI: 10.1002/iid3.391] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Mohammed ED, Zhang Z, Tian W, Gangarapu V, Al-Gendy AA, Chen J, Wei J, Sun B. Modulation of IR as a therapeutic target to prevent NASH using NRF from Diceratella elliptica (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF-kB inhibitor. Phytomedicine 2021;80:153388. [PMID: 33113501 DOI: 10.1016/j.phymed.2020.153388] [Reference Citation Analysis]
32 Qian CL, Ding CL, Tang HL, Qi ZT, Wang W. Retinoic acid induced 16 deficiency exacerbates high-fat diet-induced steatohepatitis in mice. Cell Biochem Funct 2020;38:753-60. [PMID: 32289885 DOI: 10.1002/cbf.3542] [Reference Citation Analysis]
33 Wei S, Yu X. Efficacy of resveratrol supplementation on liver enzymes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Complement Ther Med 2021;57:102635. [PMID: 33271299 DOI: 10.1016/j.ctim.2020.102635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Guo S, Yan K, Fang X, Ni Y, Ma W, Zhao R. α-Lipoic Acid Alleviates Hepatic Lipid Deposition by Inhibiting FASN Expression via miR-3548 in Rats. Nutrients 2021;13:2331. [PMID: 34371841 DOI: 10.3390/nu13072331] [Reference Citation Analysis]
35 Kurata H. Virtual metabolic human dynamic model for pathological analysis and therapy design for diabetes. iScience 2021;24:102101. [PMID: 33615200 DOI: 10.1016/j.isci.2021.102101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
36 Qiu L, Guo C. Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease. Curr Drug Targets 2020;21:599-609. [PMID: 31589122 DOI: 10.2174/1389450120666191007111712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Lorzadeh N, Kazemirad N, Kazemirad Y. Human immunodeficiency: Extragonadal comorbidities of infertility in women. Immun Inflamm Dis 2020;8:447-57. [PMID: 32621331 DOI: 10.1002/iid3.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacol Res 2021;167:105484. [PMID: 33771699 DOI: 10.1016/j.phrs.2021.105484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Guo M. Cellular senescence and liver disease: Mechanisms and therapeutic strategies. Biomed Pharmacother. 2017;96:1527-1537. [PMID: 29174037 DOI: 10.1016/j.biopha.2017.11.075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
40 Wu H, Xu X, Zheng A, Wang W, Mei L, Chen Y, Sun S, Jiang L, Wu Y, Zhou Y, Zheng M, Chen Q. TNF-α-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of Apoptosis Signal-Regulating Kinase 1. Hepatology 2021. [PMID: 33713358 DOI: 10.1002/hep.31801] [Reference Citation Analysis]
41 Sandoval-Rodriguez A, Monroy-Ramirez HC, Meza-Rios A, Garcia-Bañuelos J, Vera-Cruz J, Gutiérrez-Cuevas J, Silva-Gomez J, Staels B, Dominguez-Rosales J, Galicia-Moreno M, Vazquez-Del Mercado M, Navarro-Partida J, Santos-Garcia A, Armendariz-Borunda J. Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK. Hepatol Commun 2020;4:434-49. [PMID: 32140659 DOI: 10.1002/hep4.1474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
42 Yousefi Z, Nourbakhsh M, Abdolvahabi Z, Ghorbanhosseini SS, Hesari Z, Yarahmadi S, Ezzati-Mobasser S, Seiri P, Borji M, Meshkani R, Malek M. microRNA-141 is associated with hepatic steatosis by downregulating the sirtuin1/AMP-activated protein kinase pathway in hepatocytes. J Cell Physiol 2020;235:880-90. [PMID: 31256424 DOI: 10.1002/jcp.29002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
43 Zheng S, Yang Y, Wen C, Liu W, Cao L, Feng X, Chen J, Wang H, Tang Y, Tian L, Wang X, Yang F. Effects of environmental contaminants in water resources on nonalcoholic fatty liver disease. Environ Int 2021;154:106555. [PMID: 33857709 DOI: 10.1016/j.envint.2021.106555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
44 Cui Y, Liu J, Shi H, Hu W, Song L, Zhao Q. Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. J Diabetes Complications 2021;35:107874. [PMID: 33640265 DOI: 10.1016/j.jdiacomp.2021.107874] [Reference Citation Analysis]
45 Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1525. [PMID: 32102237 DOI: 10.3390/ijms21041525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
46 Rivera-Álvarez M, Córdova-Ramírez AC, Elías-De-La-Cruz GD, Murrieta-Álvarez I, León-Peña AA, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. Non-alcoholic fatty liver disease and thrombocytopenia IV: its association with granulocytopenia. Hematol Transfus Cell Ther 2021:S2531-1379(21)00098-5. [PMID: 34312112 DOI: 10.1016/j.htct.2021.06.004] [Reference Citation Analysis]
47 Elvira-Torales LI, García-Alonso J, Periago-Castón MJ. Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review. Antioxidants (Basel) 2019;8:E229. [PMID: 31330977 DOI: 10.3390/antiox8070229] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
48 Ryu J, Hadley JT, Li Z, Dong F, Xu H, Xin X, Zhang Y, Chen C, Li S, Guo X, Zhao JL, Leach RJ, Abdul-Ghani MA, DeFronzo RA, Kamat A, Liu F, Dong LQ. Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration. Diabetes 2021;70:1303-16. [PMID: 34162682 DOI: 10.2337/db20-1073] [Reference Citation Analysis]
49 Tian X, Ru Q, Xiong Q, Wen R, Chen Y. Catalpol Attenuates Hepatic Steatosis by Regulating Lipid Metabolism via AMP-Activated Protein Kinase Activation. Biomed Res Int 2020;2020:6708061. [PMID: 32420361 DOI: 10.1155/2020/6708061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
50 Buyco DG, Martin J, Jeon S, Hooks R, Lin C, Carr R. Experimental models of metabolic and alcoholic fatty liver disease. World J Gastroenterol 2021;27:1-18. [PMID: 33505147 DOI: 10.3748/wjg.v27.i1.1] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Lee YS, Park JS, Lee DH, Lee DK, Kwon SW, Lee BW, Bae SH. The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition. Front Endocrinol (Lausanne) 2018;9:539. [PMID: 30298052 DOI: 10.3389/fendo.2018.00539] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
52 Kutlu O, Altun Ö, Dikker O, Aktaş Ş, Özsoy N, Arman Y, Özgün Çil E, Özcan M, Aydın Yoldemir Ş, Akarsu M, Toprak İD, Kırna K, Kutlu Y, Toprak Z, Eruzun H, Tükek T. Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease. Med Princ Pract 2019;28:463-9. [PMID: 30995640 DOI: 10.1159/000500106] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
53 Akahane T, Akahane M, Namisaki T, Kaji K, Moriya K, Kawaratani H, Takaya H, Sawada Y, Shimozato N, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mitoro A, Yoshiji H. Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. J Clin Med 2020;9:E1635. [PMID: 32481684 DOI: 10.3390/jcm9061635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
54 Pyun DH, Kim TJ, Kim MJ, Hong SA, Abd El-Aty AM, Jeong JH, Jung TW. Endogenous metabolite, kynurenic acid, attenuates nonalcoholic fatty liver disease via AMPK/autophagy- and AMPK/ORP150-mediated signaling. J Cell Physiol 2021;236:4902-12. [PMID: 33283879 DOI: 10.1002/jcp.30199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Ore A, Akinloye OA, Adeogun AI, Ugbaja RN, Morifi E, Makatini M, Moepya R, Mbhele T. Buchholzia coriacea seed (wonderful kolanut) alleviates insulin resistance, steatosis, inflammation and oxidative stress in high fat diet model of fatty liver disease. J Food Biochem 2021;:e13836. [PMID: 34184286 DOI: 10.1111/jfbc.13836] [Reference Citation Analysis]
56 Li YX, Sang YQ, Sun Y, Liu XK, Geng HF, Zha M, Wang B, Teng F, Sun HJ, Wang Y, Qiu QQ, Zang X, Wang Y, Wu TT, Jones PM, Liang J, Xu W. Pancreatic Fat is not significantly correlated with β-cell Dysfunction in Patients with new-onset Type 2 Diabetes Mellitus using quantitative Computed Tomography. Int J Med Sci 2020;17:1673-82. [PMID: 32714070 DOI: 10.7150/ijms.46395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Goodus MT, McTigue DM. Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? Exp Neurol 2020;325:113160. [PMID: 31863731 DOI: 10.1016/j.expneurol.2019.113160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
58 Yung JHM, Giacca A. Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. Cells 2020;9:E706. [PMID: 32183037 DOI: 10.3390/cells9030706] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
59 Hosny SS, Ali HM, Mohammed WA, El Ghannam MH. Study of relationship between total vitamin D level and NAFLD in a sample of Egyptian patients with and without T2DM. Diabetes Metab Syndr 2019;13:1769-71. [PMID: 31235092 DOI: 10.1016/j.dsx.2019.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
60 Chen XX, Xu YY, Wu R, Chen Z, Fang K, Han YX, Yu Y, Huang LL, Peng L, Ge JF. Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression. Front Endocrinol (Lausanne) 2019;10:434. [PMID: 31338065 DOI: 10.3389/fendo.2019.00434] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
61 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
62 Dai LL, Li SD, Ma YC, Tang JR, Lv JY, Zhang YQ, Miao YL, Ma YQ, Li CM, Chu YY, Wang KH, Ma LQ, Zou CG. MicroRNA-30b regulates insulin sensitivity by targeting SERCA2b in non-alcoholic fatty liver disease. Liver Int 2019;39:1504-13. [PMID: 30721562 DOI: 10.1111/liv.14067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
63 Ramírez-Vélez R, González-Ruíz K, González-Jiménez E, Schmidt-RioValle J, Correa-Rodríguez M, García-Hermoso A, Palomino-Echeverría S, Izquierdo M. Serum leptin as a mediator of the influence of insulin resistance on hepatic steatosis in youths with excess adiposity. Nutr Metab Cardiovasc Dis 2021;31:1308-16. [PMID: 33618924 DOI: 10.1016/j.numecd.2020.12.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Kodama T, Yi J, Newberg JY, Tien JC, Wu H, Finegold MJ, Kodama M, Wei Z, Tamura T, Takehara T, Johnson RL, Jenkins NA, Copeland NG. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proc Natl Acad Sci U S A 2018;115:E10417-26. [PMID: 30327349 DOI: 10.1073/pnas.1808968115] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
65 Federico A, Dallio M, Masarone M, Gravina AG, Di Sarno R, Tuccillo C, Cossiga V, Lama S, Stiuso P, Morisco F, Persico M, Loguercio C. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. Oxid Med Cell Longev 2019;2019:8742075. [PMID: 31737175 DOI: 10.1155/2019/8742075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
66 Zamani-Garmsiri F, Ghasempour G, Aliabadi M, Hashemnia SMR, Emamgholipour S, Meshkani R. Combination of metformin and chlorogenic acid attenuates hepatic steatosis and inflammation in high-fat diet fed mice. IUBMB Life 2021;73:252-63. [PMID: 33326684 DOI: 10.1002/iub.2424] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Kazeminasab F, Marandi SM, Baharlooie M, Nasr-Esfahani MH, Ghaedi K. Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice. Nutr Metab (Lond) 2021;18:75. [PMID: 34284789 DOI: 10.1186/s12986-021-00600-0] [Reference Citation Analysis]
68 Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.Diabetol Metab Syndr. 2020;12:60. [PMID: 32684985 DOI: 10.1186/s13098-020-00570-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 35.0] [Reference Citation Analysis]
69 Zarneshan SN, Fakhri S, Farzaei MH, Khan H, Saso L. Astaxanthin targets PI3K/Akt signaling pathway toward potential therapeutic applications. Food and Chemical Toxicology 2020;145:111714. [DOI: 10.1016/j.fct.2020.111714] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
70 Zhu M, Hao S, Liu T, Yang L, Zheng P, Zhang L, Ji G. Lingguizhugan decoction improves non-alcoholic fatty liver disease by altering insulin resistance and lipid metabolism related genes: A whole trancriptome study by RNA-Seq. Oncotarget. 2017;8:82621-82631. [PMID: 29137289 DOI: 10.18632/oncotarget.19734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
71 Mohammed ED, Abdel-Naim AB, Kangpeng J, Jiang R, Wei J, Sun B. The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. Life Sci 2021;264:118615. [PMID: 33096115 DOI: 10.1016/j.lfs.2020.118615] [Reference Citation Analysis]
72 Peres Valgas da Silva C, Calmasini F, Alexandre EC, Raposo HF, Delbin MA, Monica FZ, Zanesco A. The effects of mirabegron on obesity-induced inflammation and insulin resistance are associated with brown adipose tissue activation but not beiging in the subcutaneous white adipose tissue. Clin Exp Pharmacol Physiol 2021. [PMID: 34343353 DOI: 10.1111/1440-1681.13566] [Reference Citation Analysis]
73 Okubo H, Kushiyama A, Nakatsu Y, Yamamotoya T, Matsunaga Y, Fujishiro M, Sakoda H, Ohno H, Yoneda M, Asano T. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. Int J Mol Sci 2018;19:E3064. [PMID: 30297626 DOI: 10.3390/ijms19103064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
74 Luo L, Fang K, Dan X, Gu M. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice. Lipids Health Dis 2019;18:11. [PMID: 30621686 DOI: 10.1186/s12944-018-0955-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
75 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 2018;75:3313-27. [PMID: 29936596 DOI: 10.1007/s00018-018-2860-6] [Cited by in Crossref: 234] [Cited by in F6Publishing: 192] [Article Influence: 78.0] [Reference Citation Analysis]
76 Chang TC, Chiang H, Lai YH, Huang YL, Huang HC, Liang YC, Liu HK, Huang C. Helminthostachys zeylanica alleviates hepatic steatosis and insulin resistance in diet-induced obese mice. BMC Complement Altern Med 2019;19:368. [PMID: 31836013 DOI: 10.1186/s12906-019-2782-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
77 Della Pepa G, Vetrani C, Lombardi G, Bozzetto L, Annuzzi G, Rivellese AA. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals. Nutrients 2017;9:E1065. [PMID: 28954437 DOI: 10.3390/nu9101065] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
78 Dai L, Ooi VV, Zhou W, Ji G. Acupoint embedding therapy improves nonalcoholic fatty liver disease with abnormal transaminase: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e18775. [PMID: 32011470 DOI: 10.1097/MD.0000000000018775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Wu H, Ni X, Xu Q, Wang Q, Li X, Hua J. Regulation of lipid‐induced macrophage polarization through modulating peroxisome proliferator‐activated receptor‐gamma activity affects hepatic lipid metabolism via a Toll‐like receptor 4/NF‐κB signaling pathway. Journal of Gastroenterology and Hepatology 2020;35:1998-2008. [DOI: 10.1111/jgh.15025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
80 Savari F, Mard SA, Badavi M, Rezaie A, Gharib-Naseri MK. A new method to induce nonalcoholic steatohepatitis (NASH) in mice. BMC Gastroenterol 2019;19:125. [PMID: 31307427 DOI: 10.1186/s12876-019-1041-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
81 Simoes ICM, Janikiewicz J, Bauer J, Karkucinska-Wieckowska A, Kalinowski P, Dobrzyń A, Wolski A, Pronicki M, Zieniewicz K, Dobrzyń P, Krawczyk M, Zischka H, Wieckowski MR, Potes Y. Fat and Sugar-A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E2871. [PMID: 31771244 DOI: 10.3390/nu11122871] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
82 Ma N, Ma R, Tang K, Li X, He B. Roux-en-Y Gastric Bypass in Obese Diabetic Rats Promotes Autophagy to Improve Lipid Metabolism through mTOR/p70S6K Signaling Pathway. J Diabetes Res 2020;2020:4326549. [PMID: 32309446 DOI: 10.1155/2020/4326549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Leibowitz A, Bier A, Gilboa M, Peleg E, Barshack I, Grossman E. Saccharin Increases Fasting Blood Glucose but Not Liver Insulin Resistance in Comparison to a High Fructose-Fed Rat Model. Nutrients 2018;10:E341. [PMID: 29534506 DOI: 10.3390/nu10030341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
84 Lin E, Huang X, Pei Z, Gross J, Popov V. Intragastric Balloon Improves Steatohepatitis and Fibrosis. ACG Case Rep J 2021;8:e00534. [PMID: 33490302 DOI: 10.14309/crj.0000000000000534] [Reference Citation Analysis]
85 Chen C, Zhu Z, Mao Y, Xu Y, Du J, Tang X, Cao H. HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels. Biosci Rep 2020;40:BSR20193996. [PMID: 31940026 DOI: 10.1042/BSR20193996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
86 El‐deen RM, Heeba GH, Abdel‐latif RG, Khalifa MM. Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high‐fat diet‐induced nonalcoholic fatty liver in rats. Fundam Clin Pharmacol 2020;34:353-64. [DOI: 10.1111/fcp.12530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Hasegawa T, Iino C, Endo T, Mikami K, Kimura M, Sawada N, Nakaji S, Fukuda S. Changed Amino Acids in NAFLD and Liver Fibrosis: A Large Cross-Sectional Study without Influence of Insulin Resistance. Nutrients 2020;12:E1450. [PMID: 32429590 DOI: 10.3390/nu12051450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
88 Khurana P, Yadati T, Goyal S, Dolas A, Houben T, Oligschlaeger Y, Agarwal AK, Kulkarni A, Shiri-Sverdlov R. Inhibiting Extracellular Cathepsin D Reduces Hepatic Steatosis in Sprague⁻Dawley Rats . Biomolecules 2019;9:E171. [PMID: 31060228 DOI: 10.3390/biom9050171] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
89 Zhou Y, Li P, Wang X, Wu C, Fan N, Liu X, Wu L, Zhang W, Zhang W, Liu Z, Tang B. In situ visualization of peroxisomal viscosity in the liver of mice with non-alcoholic fatty liver disease by near-infrared fluorescence and photoacoustic imaging. Chem Sci 2020;11:12149-56. [PMID: 34094429 DOI: 10.1039/d0sc02922j] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 15.0] [Reference Citation Analysis]
90 Tengeler AC, Gart E, Wiesmann M, Arnoldussen IAC, van Duyvenvoorde W, Hoogstad M, Dederen PJ, Verweij V, Geenen B, Kozicz T, Kleemann R, Morrison MC, Kiliaan AJ. Propionic acid and not caproic acid, attenuates nonalcoholic steatohepatitis and improves (cerebro) vascular functions in obese Ldlr-/- .Leiden mice. FASEB J 2020;34:9575-93. [PMID: 32472598 DOI: 10.1096/fj.202000455R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
91 Ramos-Tovar E, Muriel P. Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage. J Appl Toxicol 2020;40:151-68. [PMID: 31389060 DOI: 10.1002/jat.3880] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
92 Wan M, Han J, Ding L, Hu F, Gao P. Novel Immune Subsets and Related Cytokines: Emerging Players in the Progression of Liver Fibrosis. Front Med (Lausanne) 2021;8:604894. [PMID: 33869241 DOI: 10.3389/fmed.2021.604894] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
93 Ye X, Kong W, Zafar MI, Zeng J, Yang R, Chen LL. Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction. EXCLI J 2020;19:1186-95. [PMID: 33408593 DOI: 10.17179/excli2020-2647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Fontana L, Plaza-Díaz J, Robles-Bolívar P, Valente-Godínez H, Sáez-Lara MJ, Abadía-Molina F, Gómez-Llorented C, Gil Á, Álvarez-Mercado AI. Bifidobacterium breve CNCM I-4035, Lactobacillus paracasei CNCM I-4034 and Lactobacillus rhamnosus CNCM I-4036 Modulate Macrophage Gene Expression and Ameliorate Damage Markers in the Liver of Zucker-Lepr fa/fa Rats. Nutrients 2021;13:202. [PMID: 33440736 DOI: 10.3390/nu13010202] [Reference Citation Analysis]
95 Akahane T, Namisaki T, Kaji K, Moriya K, Kawaratani H, Takaya H, Sawada Y, Shimozato N, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Ogawa H, Takagi H, Ishida K, Yoshiji H. Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. Nutrients 2020;12:E1036. [PMID: 32283773 DOI: 10.3390/nu12041036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
96 Zhu B, Mei W, Jiao T, Yang S, Xu X, Yu H, Ding Y, Guo S, Meng B, Zhao L, He M, Dong K, Guo H, Guo X, Zhang H, Dang R, Xiang G, Wen N. Neuregulin 4 alleviates hepatic steatosis via activating AMPK/mTOR-mediated autophagy in aged mice fed a high fat diet. Eur J Pharmacol 2020;884:173350. [PMID: 32726654 DOI: 10.1016/j.ejphar.2020.173350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Oyarzún JE, Andia ME, Uribe S, Núñez Pizarro P, Núñez G, Montenegro G, Bridi R. Honeybee Pollen Extracts Reduce Oxidative Stress and Steatosis in Hepatic Cells. Molecules 2020;26:E6. [PMID: 33374984 DOI: 10.3390/molecules26010006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
98 Rashed ZE, Grasselli E, Khalifeh H, Canesi L, Demori I. Brown-Algae Polysaccharides as Active Constituents against Nonalcoholic Fatty Liver Disease. Planta Med 2020. [PMID: 33142346 DOI: 10.1055/a-1273-3159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
99 Xu L, Li T, Yin J, Lin G, Xu Y, Ren Y, Wang Y, Yang J, Chen L. Association between serum uric acid and nonalcoholic fatty liver disease in community patients with type 2 diabetes mellitus. PeerJ 2019;7:e7563. [PMID: 31523513 DOI: 10.7717/peerj.7563] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
100 Wu SJ, Huang WC, Yu MC, Chen YL, Shen SC, Yeh KW, Liou CJ. Tomatidine ameliorates obesity-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem 2021;91:108602. [PMID: 33548473 DOI: 10.1016/j.jnutbio.2021.108602] [Reference Citation Analysis]
101 Beaudry KM, Devries MC. Sex-based differences in hepatic and skeletal muscle triglyceride storage and metabolism 1. Appl Physiol Nutr Metab 2019;44:805-13. [PMID: 30702924 DOI: 10.1139/apnm-2018-0635] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
102 Kuryłowicz A, Koźniewski K. Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes. Molecules 2020;25:E2224. [PMID: 32397353 DOI: 10.3390/molecules25092224] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
103 He X, Gao J, Hou H, Qi Z, Chen H, Zhang X. Inhibition of Mitochondrial Fatty Acid Oxidation Contributes to Development of Nonalcoholic Fatty Liver Disease Induced by Environmental Cadmium Exposure. Environ Sci Technol 2019;53:13992-4000. [DOI: 10.1021/acs.est.9b05131] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
104 Fawzy MH, Saeed NM, El-Sherbiny DA, El-Demerdash E. Eugenol modulates insulin sensitivity by upregulating insulin receptor substrate-2 in non-alcoholic fatty liver disease in rats. J Pharm Pharmacol 2021;73:846-54. [PMID: 33822104 DOI: 10.1093/jpp/rgab032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Semmler G, Bachmayer S, Wernly S, Wernly B, Niederseer D, Huber-Schönauer U, Stickel F, Aigner E, Datz C. Nut consumption and the prevalence and severity of non-alcoholic fatty liver disease. PLoS One 2020;15:e0244514. [PMID: 33382757 DOI: 10.1371/journal.pone.0244514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Jirapinyo P, Mccarty TR, Dolan RD, Shah R, Thompson CC. Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.03.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Kimura K, Inaba Y, Watanabe H, Matsukawa T, Matsumoto M, Inoue H. Nicotinic alpha-7 acetylcholine receptor deficiency exacerbates hepatic inflammation and fibrosis in a mouse model of non-alcoholic steatohepatitis. J Diabetes Investig 2019;10:659-66. [PMID: 30369082 DOI: 10.1111/jdi.12964] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
108 Rial SA, Jutras-carignan A, Bergeron K, Mounier C. A high-fat diet enriched in medium chain triglycerides triggers hepatic thermogenesis and improves metabolic health in lean and obese mice. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2020;1865:158582. [DOI: 10.1016/j.bbalip.2019.158582] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
109 Mazibuko-Mbeje SE, Dludla PV, Johnson R, Joubert E, Louw J, Ziqubu K, Tiano L, Silvestri S, Orlando P, Opoku AR, Muller CJF. Aspalathin, a natural product with the potential to reverse hepatic insulin resistance by improving energy metabolism and mitochondrial respiration. PLoS One 2019;14:e0216172. [PMID: 31048842 DOI: 10.1371/journal.pone.0216172] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
110 Latenstein CSS, Alferink LJM, Darwish Murad S, Drenth JPH, van Laarhoven CJHM, de Reuver PR. The Association Between Cholecystectomy, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Clin Transl Gastroenterol 2020;11:e00170. [PMID: 32352682 DOI: 10.14309/ctg.0000000000000170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
111 Wang F, Park JS, Ma Y, Ma H, Lee YJ, Lee GR, Yoo HS, Hong JT, Roh YS. Ginseng Saponin Enriched in Rh1 and Rg2 Ameliorates Nonalcoholic Fatty Liver Disease by Inhibiting Inflammasome Activation. Nutrients 2021;13:856. [PMID: 33807927 DOI: 10.3390/nu13030856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Zhang S, Fu J, Zhang Q, Liu L, Meng G, Yao Z, Wu H, Bao X, Gu Y, Lu M, Sun S, Wang X, Zhou M, Jia Q, Song K, Xiang H, Wu Y, Niu K. Association between nut consumption and non-alcoholic fatty liver disease in adults. Liver Int 2019;39:1732-41. [PMID: 31162803 DOI: 10.1111/liv.14164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
113 Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int 2018;2018:3140983. [PMID: 29546055 DOI: 10.1155/2018/3140983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
114 Ni Y, Zhuge F, Nagashimada M, Nagata N, Xu L, Yamamoto S, Fuke N, Ushida Y, Suganuma H, Kaneko S, Ota T. Lycopene prevents the progression of lipotoxicity-induced nonalcoholic steatohepatitis by decreasing oxidative stress in mice. Free Radic Biol Med 2020;152:571-82. [PMID: 31790829 DOI: 10.1016/j.freeradbiomed.2019.11.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
115 Hari Kumar KVS. The good, the bad, and the ugly facets of insulin resistance. Med J Armed Forces India 2020;76:4-7. [PMID: 32020961 DOI: 10.1016/j.mjafi.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
116 Zhu S, Wang Y, Luo F, Liu J, Xiu L, Qin J, Wang T, Yu N, Wu H, Zou T. The Level of Vitamin D in Children and Adolescents with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Biomed Res Int 2019;2019:7643542. [PMID: 31380438 DOI: 10.1155/2019/7643542] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
117 Liou CJ, Lee YK, Ting NC, Chen YL, Shen SC, Wu SJ, Huang WC. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet. Cells 2019;8:E447. [PMID: 31083505 DOI: 10.3390/cells8050447] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]